These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 33956969)

  • 21. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter surveillance of
    Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
    Le Terrier C; Nordmann P; Buchs C; Poirel L
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
    Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.
    Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
    Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
    Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
    Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
    Bhagwat SS; Hariharan P; Joshi PR; Palwe SR; Shrivastava R; Patel MV; Devanga Ragupathi NK; Bakthavatchalam YD; Ramesh MS; Soman R; Veeraraghavan B
    J Antimicrob Chemother; 2020 Dec; 75(12):3563-3567. PubMed ID: 32772098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
    Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
    Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in
    Sadek M; Bosch Duran J; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
    Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
    Nordmann P; Bouvier M; Poirel L
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
    Blanco-Martín T; López-Hernández I; Aracil B; González-Pinto L; Aja-Macaya P; Alonso-García I; Rodríguez-Pallares S; Sánchez-Peña L; Outeda-García M; Pérez-Vázquez M; Vázquez-Ucha JC; Beceiro A; Pascual Á; Bou G; López-Cerero L; Oteo-Iglesias J; Arca-Suárez J;
    Antimicrob Agents Chemother; 2024 Oct; ():e0092424. PubMed ID: 39382274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
    Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.